Health benefits of late-onset metformin treatment every other week in mice
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Chronic 1% metformin treatment is nephrotoxic in mice, but this dose may nonetheless confer health benefits if given intermittently rather than continuously. Here, we examined the effects of 1% metformin given every-other week (EOW) or two consecutive weeks per month (2WM) on survival of 2-year-old male mice fed standard chow. EOW and 2WM mice had comparable life span compared with control mice. A significant reduction in body weight within the first few weeks of metformin treatment was observed without impact on food consumption and energy expenditure. Moreover, there were differences in the action of metformin on metabolic markers between the EOW and 2WM groups, with EOW metformin conferring greater benefits. Age-associated kidney lesions became more pronounced with metformin, although without pathological consequences. In the liver, metformin treatment led to an overall reduction in steatosis and was accompanied by distinct transcriptomic and metabolomic signatures in response to EOW versus 2WM regimens. Thus, the absence of adverse outcomes associated with chronic, intermittent use of 1% metformin in old mice has clinical translatability into the biology of aging in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intermittent metformin treatment, when initiated in mice, even later in life and administered every other week, has also shown to provide health benefits such as a reduction in hepatic steatosis through regulation of the liver transcriptome and metabolome”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Alfaras et al. 2017
In the citing paper
“For instance, as discussed in the next section, despite activating AMPK, metformin has not reproducibly been shown to enhance lifespan in rodents and notably less, or not effective in older animals, including C. elegans (66, 72, 74, 75, 77, 78).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“In contrast, inhibition of mTOR activity with concurrent activation of AMPK by rapamycin prolongs lifespan even when given in old mice.(66) Therefore, metformin and rapalogs may exert cooperative effects at the level of the energy-sensing AMPK and diminished expenditure of cellular energy required for protein translat…”
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445 · cited 10×
“Metformin is a calorie restriction (CR) mimetic, with several of its metabolic actions, particularly those related to glucose metabolism, resembling to some extent those of CR.2,3,20,21 Our previous study showed that diet supplementation with a low dose of metformin (0.1% w/w) improves healthspan and extends lifespan…”
InfluentialSelf-citationEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 2×
“The primary target of metformin appears to be the mitochondrion through inhibition of complex I of the respiratory chain(7,8) and mitochondrial glycerol-3-phosphate dehydrogenase.(9) The ensuing perturbations in cellular energy status and redox homeostasis result in activation of the energy sensor AMP-activated protei…”
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“The anti-gluconeogenic action of metformin is preserved in liverspecific AMPK knockout mice.(13) Moreover, this biguanide confers protection against certain cancers by inhibiting mTOR/p70S6K activity in an AMPK-independent manner,(15) and reduces the tumorigenicity of induced pluripotent stem cells while maintaining t…”
Analysis of Microarray Data Using Z Score Transformation
Cheadle, C., Vawter, M. P., Freed, W. J., & Becker, K. G. (2003) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60455-2 · Cited by 1,146 · cited 1×
“Microarray analysis Raw data were subjected to Z-normalization, as described elsewhere.(72,73) PCA was performed on the normalized Z-scores of all of the detectable probes in the samples using DIANE 6.”
Cited by
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
“also shown to provide health benefits such as a reduction in hepatic steatosis through regulation of the liver transcriptome and metabolome (Alfaras et al. 2017).”
BackgroundMohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
“(75) • Intermittent [either every other week (EOW) or two weeks out of 4”
BackgroundMetformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Wahl, D., Solon-Biet, S. M., Cogger, V. C., Fontana, L., Simpson, S. J., Le Couteur, D. G., & Ribeiro, R. V. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104481 · Cited by 144
Self-citationA toolbox for the longitudinal assessment of healthspan in aging mice
Bellantuono, I., de Cabo, R., Ehninger, D., Di Germanio, C., Lawrie, A., Miller, J., Mitchell, S. J., Navas-Enamorado, I., Potter, P. K., Tchkonia, T., et al. (2020) · Nature Protocols · doi:10.1038/s41596-019-0256-1 · Cited by 145
Self-citation
Metadata
- Authors
- Alfaras, I., Mitchell, S. J., Mora, H., Lugo, D. R., Warren, A., Navas-Enamorado, I., Hoffmann, V., Hine, C., Mitchell, J. R., Le Couteur, D. G., Cogger, V. C., Bernier, M., & de Cabo, R.
- Affiliations
- National Institutes of Health (US)
- Anzac Research Institute (AU)
- Harvard University (US)
- The University of Sydney (AU)
- Corresponding author
- Bernier, Michel
- ORCID
- Venue
- npj Aging and Mechanisms of Disease
- Published
- 2017-11-20
- Volume
- 3
- Issue
- 1
- Pages
- 16-16
- ISSN
- 2056-3973 (ISSN-L)
- PMC
- PMC5696465
- OpenAlex
- W2769721119
- Cited by
- 68
- References
- 74
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 5 · 2021: 15 · 2020: 12 · 2019: 8 · 2018: 2
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Aging and Mechanisms of Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Institute on Aging
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Keywords
- metformin, intermittent dosing, aging, longevity, nephrotoxicity, hepatic steatosis, weight loss, energy expenditure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health benefits of late-onset metformin treatment every other week in mice. https://app.cochat.ai/papers/10.1038/s41514-017-0018-7
- The paper
- Alfaras, I., Mitchell, S. J., Mora, H., Lugo, D. R., Warren, A., Navas-Enamorado, I., Hoffmann, V., Hine, C., Mitchell, J. R., Le Couteur, D. G., Cogger, V. C., Bernier, M., & de Cabo, R. (2017). Health benefits of late-onset metformin treatment every other week in mice. npj Aging and Mechanisms of Disease. https://doi.org/10.1038/s41514-017-0018-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.